News
Public · Published
Ultragenyx Pharma Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley maintained its Equal-Weight rating on Ultragenyx Pharma. A separate ratings-action line says the bank raised its price target to $22.00 per share from $20.00. The supplied item gives no explanation for either action.
Published:
Updated:
What happened
Morgan Stanley maintained its Equal-Weight rating on Ultragenyx Pharma. A separate ratings-action line says the bank raised its price target to $22.00 per share from $20.00. The supplied item gives no explanation for either action.
Confirmed
Global impact / market context
The higher price target signals Morgan Stanley sees a higher potential share value than before, while Equal-Weight indicates its rating was maintained rather than upgraded. Investors may distinguish the more optimistic valuation from the unchanged overall rating when judging the stock.
Analyst inference
The item reports an analyst opinion, not a company earnings update or a change in business operations. It provides no reasoning, forecast assumptions, or industry comparisons, so it cannot show whether the target increase reflects expected revenue, costs, or development progress.
Analyst inference
What to watch
- Check for Morgan Stanley’s stated reasoning and assumptions behind the $22.00 target; these would clarify what expected company results or risks support its higher valuation. Analyst inference
- Watch for later ratings or target changes from Morgan Stanley, while treating this item as maintaining Equal-Weight rather than announcing an upgrade. Analyst inference
- Look for company updates on revenue, spending, and development progress; the supplied ratings notice does not identify these as reasons for Morgan Stanley’s action. Analyst inference
Evidence
- Original source link unavailable